

Pharnext's Pivotal Phase 3 trial PLEO-CMT to be featured at the 22nd Edition of the Francophone Peripheral Nerve Society conference

PARIS, France, 5:45 pm, January 18, 2018 (CET) – Pharnext SA (FR001191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France).

Details of the presentation are as follows:

Date	Time	Session
Friday January 26, 2018	From 3:03 to 3:15pm CET	Selected Oral Communications Session <ul style="list-style-type: none">• Title: Status of the Pivotal Phase III Study (PLEO-CMT) Assessing the Efficacy and Safety of PXT3003 in the Treatment of Adult Patients with Charcot-Marie-Tooth type 1A• Speaker : Prof. Shahram Attarian (Marseille)

For more information about the event please visit : www.journeessfnp.fr/programme

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property, including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR001191287).

For more information, visit www.pharnext.com.

CONTACTS:

Pharnext

René Goedkoop
Chief Medical Officer
medical@pharnext.com
+33 (0)1 41 09 22 30

Investor Relations (Europe)

MC Services AG
Anne Hennecke
anne.hennecke@mc-services.eu
+49 211 529252 22

Media Relations (Europe)

ALIZE RP
Caroline Carmagnol
Aurore Gangloff
pharnext@alizerp.com
+33 (0)1 44 54 36 64

Investor Relations (U.S.)

Stern Investor Relations, Inc.
Matthew Shinseki
matthew@sternir.com
+1 212 362 1200

Media Relations (U.S.)

RooneyPartners
Marion Janic
mjanic@rooneyco.com
+1 212 223 4017

Financial Communication (France)

Actifin
Stéphane Ruiz
sruiz@actifin.fr
+33 (0)1 56 88 11 15